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ABSTRACT
Genome-wide association studies (GWAS) have
identified single nucleotide polymorphisms (SNPs)
associated with increased risk for colorectal cancer
(CRC). A molecular understanding of the functional
consequences of this genetic variation is compli-
cated because most GWAS SNPs are located in non-
coding regions. We used epigenomic information
to identify H3K27Ac peaks in HCT116 colon cancer
cells that harbor SNPs associated with an increased
risk for CRC. Employing CRISPR/Cas9 nucleases, we
deleted a CRC risk-associated H3K27Ac peak from
HCT116 cells and observed large-scale changes in
gene expression, resulting in decreased expression
of many nearby genes. As a comparison, we showed
that deletion of a robust H3K27Ac peak not associ-
ated with CRC had minimal effects on the transcrip-
tome. Interestingly, although there is no H3K27Ac
peak in HEK293 cells in the E7 region, deletion of this
region in HEK293 cells decreased expression of sev-
eral of the same genes that were downregulated in
HCT116 cells, including the MYC oncogene. Accord-
ingly, deletion of E7 causes changes in cell culture
assays in HCT116 and HEK293 cells. In summary, we
show that effects on the transcriptome upon deletion
of a distal regulatory element cannot be predicted by
the size or presence of an H3K27Ac peak.
INTRODUCTION
In our previous studies, we identified a set of enhancers (de-
fined as the presence of a H3K27Ac peak located farther
than +/− 2 kb from a transcription start site) that harbor
single nucleotide polymorphisms (SNPs) associated with an
increased risk for colon cancer (1). Our working hypothesis
is that the different nucleotide sequence between the ‘risk-
associated’ vs. ‘non risk-associated’ SNPs affects activity of
the enhancers, causing a change in expression in genes (cod-
ing or non-coding) that can influence the balance between
normal tissue proliferation or differentiation versus tumor
initiation or progression. Enhancers are composed of bind-
ing sites for many different site-specific DNA binding tran-
scription factors (TFs) that are thought to work in concert
to provide cell type-specific functionality. For example, one
of the first characterized mammalian enhancers is the in-
terferon  enhanceosome, which is bounded by eight dif-
ferent TFs (2,3). Recent studies from the ENCODE Project
(4) and the Roadmap Epigenome Mapping Consortia (5)
have identified hundreds of thousands of enhancers, most of
which includemotifs for a variety of different TFs. The over-
all function of a given enhancer is dependent upon several
conditions, such as the number of motifs contained within
it, the extent to which the nucleotides within the enhancer
match consensus binding motifs, the expression level of the
TFs that bind those motifs and the location of the enhancer
with respect to chromatin boundaries. Because many TFs
contribute to the overall function of an enhancer, it is likely
that single nucleotide changes within an enhancer will have
quite modest effects on the transcriptional output from a
target promoter (6). Although modest effects in gene ex-
pression could have strong phenotypic outcomes over the
course of a long time period, such as during tumor develop-
ment, the consequences of a single nucleotide change in an
enhancer may be difficult to observe in short term cell cul-
ture assays. Thus, rather than analyzing the effect of a single
SNP, our approach is to determine the functional role of the
enhancer as a whole by identifying genes that are respon-
sive to loss of the enhancer in colon cancer cells. For com-
parison, we also analyzed an enhancer not associated with
colorectal cancer (CRC) and a distal region that lacks the
H3K27Ac mark. We show that deletion of distal regulatory
elements associated with CRC can affect nearby genes and
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also have genome-wide effects on the transcriptome. Our
results also suggest that effects on the transcriptome upon
deletion of a distal regulatory element cannot be predicted
by the size or presence of an H3K27Ac peak.
MATERIALS AND METHODS
Cell culture
The human cell lines (control and enhancer-deleted ver-
sions) HCT116 (ATCC #CCL-247) and HEK293 (ATCC
#CRL-1573) were grown at 37◦, in 5% CO2 in Dulbecco’s
Modified Eagle Medium with 10% fetal bovine serum and
1% penicillin and streptomycin.
CRISPR/Cas9-mediated genome editing
The guide RNAs (gRNAs) flanking the target enhancer re-
gions were designed using a website tool (http://crispr.mit.
edu), avoiding repeat regions in the hg19 genome. After
identification of a potential guide RNA, the 16–17 nt re-
gion including the PAM sequence (NGG) was BLASTed
against the hg19 genome to confirm that it was unique in
the genome; all guide RNAs used in this study also did not
have a 1 mismatch sequence in the human genome. The tar-
get DNA sequences of the gRNAs used in this study are
listed in Additional File 1. The 100 bp oligonucleotides con-
taining the gRNA sequences were inserted into the gRNA
Empty Vector (Addgene, catalog#41824) according to the
gRNA synthesis protocol (7). The sequences of gRNA ex-
pression plasmids were confirmed through Sanger sequenc-
ing. To delete an enhancer, two gRNA plasmids and a plas-
mid expressing Cas9-GFP (Addgene, catalog #44719) were
transiently transfected into HCT116 or HEK293 cells in a
6-well plate with a Cas9: gRNAs molar ratio of 1:22 using
Lipofectamine 3000 (Life Technologies, catalog #3000008).
Genomic DNA was extracted from the transfected cells 48
h post-transfection using the QIAamp DNA mini kit (Qi-
agen, catalog# 51306). Subsequently, polymerase chain re-
action (PCR) using primers flanking the target enhancer re-
gions was performed to check the deletion efficiency. Once
enhancer deletion was confirmed in a pool of transfected
cells, cells with high Green Fluorescent Protein (GFP) ex-
pression were identified using fluorescence-activated cell
sorting with the Aria II cell sorter (BD Biosciences). Sorted
cells were plated into individual wells of a 24-well plate and
then re-plated as single cells in 10 cm dishes and subse-
quently expanded for further analyses.
PCR detection of cells having enhancer deletions
Clonal colonies from the 10 cm dishes were transferred and
passaged into 24-well plates. When cells were 80–90% con-
fluent, genomic DNA was isolated from each clone using
the QIAamp DNA mini kit (Qiagen, catalog# 51306) and
tested for deletion by PCR using GoTaq GreenMasterMix
(Promega, catalog#M712) and primers flanking the tar-
get enhancer region. For those colonies that showed loss
of the enhancer region, a second PCR was performed us-
ing primers that should detect the inner portion of the en-
hancer. In general, <10% of the clones tested after sort-
ing for high GFP levels showed biallelic deletion. For the
E7CRC-associated enhancer,H3K27AcChIP-seq datawas
also used to confirm loss of the enhancer signal (Additional
File 2).
RNA-seq
RNA samples were collected from cells using Trizol (Life
Technologies, catalog #15596018) from clonal population.
To remove batch effects, matched controls and deleted sam-
ples were plated with similar confluency and harvested at
the same time, RNA was extracted at the same time, RNA
libraries were prepared at the same time and barcoded li-
braries were pooled and sequenced together (see Additional
File 3). All RNA libraries were prepared using the Illumina
TruSeqV2 Sample Prep Kit (catalog #15596–026), start-
ing with 1 g total RNA. ERCC spike-in mix (Thermo
Fisher, catalog # 4456740) was added when the libraries
were made so that quality assessment could be performed
on theRNA-seq data, which allowed the removal of outliers
caused by technical variations. Libraries were sequenced
on a Nextseq500 with 75 bp single reads. Raw reads were
trimmed using the Quality Score method (minimal qual-
ity score 20, minimal read length 25, trimming from both
ends) and mapped to hg19 (Ensembl 72) using Tophat2 (8)
installed in the Partek Flow version 3 program (Partek Inc.,
St Louis, MO, USA). A matrix of raw fragments counts
for each gene was generated from alignment files using HT-
Seq python package (9) withGenecode V19 annotation and
these counts were used for differential gene expression anal-
ysis using an edgeR program (10). For the group of large
datasets (Set A; see Additional File 3), where there are 12
controls versus 3 samples, genes with at least 1 counts per
million (CPM) in at least 6 samples were kept for differential
gene expression analysis. For groups of small datasets (Sets
B andC;Additional File 3), consisting of 2 controls versus 2
samples, genes with at least 1 CPM in at least 2 samples were
kept for differential gene expression analysis. In dataset A,
after removing lowly counted genes, upper-quartile normal-
ization was used for the GLM approach in edgeR which
takes into account other covariates (e.g. date of RNA ex-
traction; see Additional File 4) found in the PCA plots. For
datasets B and C, filtered gene counts were normalized us-
ing the Trimmed Mean of M-value (TMM) method for the
negative binomialmodel in edgeR.Among the differentially
expressed genes with an FDR<0.05, lowly expressed genes
were filtered out if the average CPM or average RPKM val-
ues (quantified using Partek software) was less than two in
the controls for downregulated genes or two in the deleted
samples for upregulated genes. Finally, genes with>1.5-fold
change were defined as differentially expressed genes (i.e.
the numbers shown in Table 1).
Cell assays
Controls and E7-deleted HCT116 cells were counted by
sorting single cells using a flow cytometer and then plated
into a 96-well plate at a density of 1 × 104 or 2.5 × 103 cells
per well. After 72 or 96 h, cells were rinsed with 1× PBS
and then 100 l of PBS mixed with 10 l of WST-1 reagent
(Roche, catalog # 05015944001) was added to each well.
Cell proliferation was measured using a microplate reader
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E7 590 0 565 5 FAM84B 7.45 1.50 −843 000
CCAT1 2.79 1.78 −182 000
CASC8 2.33 1.55 81 000
MYC 112.3 2.31 335 000
PVT1 7.96 1.59 395 000
E7 (HEK293) 166 0 295 1 MYC 28.5 5.10 335 000
18qE 13 0 3 0 N/A N/A N/A N/A
18qNE 14 0 3 0 N/A N/A N/A N/A
Altered gene expression upon enhancer deletion. The number of genes having>1.5 fold increase or decrease in expression in the genome and within +/− 1Mb after deletion of each distal region is indicated.
Also shown are the names of the putative direct target genes, the average RPKM values for these genes in the control cells, the fold decrease in the enhancer-deleted cells and the distance of these genes from
the distal regions.
(HIDEX Chameleon V4.43) after incubation for 15 min at
37◦C. The wavelength for measuring the absorbance of for-
mazan, the product of the WST-1 assay, was 450 nm.
Colony forming assays
HCT116 cells and HEK293 cells were counted by sorting
single cells using a flow cytometer and were seeded in 6-
well plates at a density of 1.5 × 103 cells per well and 6.5
× 103 cells per well, respectively. After a 2 week incubation,
cells were fixedwith 100%methanol for 10min, stainedwith
0.5% crystal violet for 30 min, and colonies were assessed
after rinsing the plates with water.
ChIP-seq and analysis
H3K27Ac ChIP-seq data from HCT116 cells (ENCODE
accession number ENCSR000EUT) was downloaded from
the UCSC genome browser and analyzed using the Sole-
search ChIP-seq peak calling program (11,12) using the fol-
lowing parameters (Permutation:5; Fragment:250; Value:
0.00010= 1.0E-4; FDR: 0.00010= 1.0E-4; PeakMergeDis-
tance:0; HistoneBlurLength:1200). H3K27Ac ChIP-seq
samples for control and enhancer-deleted HCT116 cells
were prepared using an H3K27Ac antibody (Active mo-
tif catalog#39133, Lot#21311004), as previously described
(13), with minor modifications (complete protocol available
upon request). These ChIP-seq libraries were sequenced
on a HiSeq2000 with 50 bp single end reads. All ChIP-
seq FASTQ files were mapped to hg19 using BWA (default
parameters). To identify decreased or increased H3K27Ac
peaks in enhancer-deleted cells, two biological replicates for
each group were used for differential peak analysis. A peak-
calling prioritization pipleline (PePr) was used to identify
significant differential binding sites of H3K27Ac caused
by enhancer deletions (14); default parameters for histone
marks were used for analysis and differential peaks having
a p-value less than 1e−5 are reported.
RESULTS
Deletion of CRC risk-associated enhancers can cause
widespread effects on the transcriptome
We have chosen to use HCT116 colon cancer cells for our
analysis of CRC risk-associated enhancers because of the
availability of histonemodification data (15), whole genome
DNAmethylation data (16), and ChIP-seq TF binding sites
(4) from these cells. Of the previously identified 28 CRC
risk-associated enhancers, 14 are detected in HCT116 cells.
However, they are not necessarily amongst the top ranked
enhancers in HCT116 cells (Figure 1A). Interestingly, 12
of the 14 CRC risk-associated enhancers in HCT116 cells
are located within the introns of 6 protein-coding genes
and 1 non-coding RNA, whereas 2 of the enhancers are
intergenic. In HCT116 cells, ∼50% of all H3K27Ac en-
hancers are intronic (16); it is not clear if the high pre-
ponderance of intronic enhancers in the set of CRC risk-
associated enhancers is due to a bias involving the choice
of index SNPs on the GWAS array or due to a biological
or functional reason. However, others have also observed
that GWAS SNPs (and SNPs in high linkage disequilibrium
with GWAS index SNPs) are more enriched in introns than
in intergenic regions (17). We selected to study a risk en-
hancer, which resides in an intron of the non-coding RNA
CASC8 (enhancer E7, identified by rs6983267) for targeted
deletion (Figure 1B). Although the function of CASC8 is
not known, SNPs within the long non-codingRNACASC8
have also been implicated in increased risk for gastric and
breast cancer (18). However, enhancers can work at a long
distance and in either orientation and thus it is not certain
that the gene in which an enhancer resides is in fact reg-
ulated by that enhancer (19–22). For example, in a ChIA-
PET study using an antibody for RNA polymerase II, Li et
al. (23) identified∼20 000–30 000 enhancer–promoter loops
in MCF7 or K562 cells. Of these, more than 40% of the en-
hancers skipped over the nearest gene to loop to a farther
one. Of course, it is not been proven that all loops repre-
sent bona fide regulatory interactions or that all enhancer-
mediated regulation involves looping (24). However, these
studies indicate that it is not a certainty that the genes
in which the enhancers reside are the ones that should be
linked to an increased risk for colon cancer. To gain fur-
ther insight into the mechanisms by which the CRC risk-
associated enhancers may influence tumor development, we
analyzed gene expression changes in clonal populations of
cells lacking E7.
An overview of the strategy used to determine the func-
tion of enhancers is shown in Figure 2. Guide RNAs were
designed that flank the H3K27Ac marks of an enhancer;
see Additional File 1 for the genomic location and the se-
quences of all guide RNAs used in this study. Plasmids ex-
pressing the guide RNAs and Cas9-GFP were transfected
into cells, 48 h later cells were sorted for high GFP expres-
sion and colonies were grown from single cells. PCR anal-
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Figure 1. Genomic location and H3K27Ac profiles of E7, 18qE and 18qNE. (A) Shown is a graph representing HCT116 H3K27Ac peaks, as identified
using Sole-search (11,12) to analyze the HCT116 H3K27Ac ChIP-seq data; all 35 932 peaks were plotted based on peak height (Y axis) versus peak rank
(X axis). The locations of the 14 CRC risk-associated enhancers present in HCT116 cells are shown (orange circles), with the large red circle indicating the
CRC risk-associated enhancer deleted in this study. Also shown is the location of the H3K27Ac peak called 18qE (blue circle); the green circle indicates
that the 18qNE region was not called as a peak. (B) For the distal regions deleted in this study, the genomic location, the H3K27Ac pattern in HCT116
cells, the combined H3K27Ac pattern in multiple cell types (the ENCODE Regulation Layered H3K27Ac track) and TF binding data (the ENCODE
Regulation Txn Factor ChIP track combines ENCODE ChIP-seq data from many different transcription factors (TFs) and cell lines in a relatively dense
display) from the UCSC genome browser are shown; the boxes indicate the approximate region that was deleted.
Figure 2. Experimental schema. The overall approach used to analyze the function of an enhancer is shown, beginning with design of guide RNAs used
to guide Cas9 to the targeted enhancers and ending with RNA-seq analysis of control and enhancer-deleted cells.
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ysis using a set of primers that flank the targeted genomic
region and a set of primers internal to the targeted region
were used to identify clonal lines having deletion of the tar-
geted region (Additional File 2). In general, <10% of the
clones tested after sorting for high GFP levels showed dele-
tion of all alleles. After confirming that the targeted region
had been deleted, RNA-seq was performed to identify gene
expression differences between the cells with enhancer dele-
tion versus the control cells. We prepared control samples
from four different clonal populations of FACS-selected
HCT116 cells that had been transfected with Cas9-GFP
plus the guide RNA vector lacking inserted guide RNAs.
Each control clonewas analyzed usingRNApreps prepared
from cell cultures grown on different days. For enhancer-
deleted cells, we also prepared triplicate RNA samples from
cells grown on the same days as the control clones, and se-
quenced matched control and deleted samples in the same
lane of a sequencer to prevent batch effects. Information
concerning all RNA-seq data sets analyzed in this study can
be found in Additional File 3, quality control plots for the
RNA-seq data can be found in Additional File 4 and gene
expression data can be found in Additional File 5.
The E7 CRC risk-associated enhancer harbors a GWAS
CRC index SNP and resides near, but not within, a region
that contains a large number of super-enhancers (see Fig-
ure 3). Due to the small size of the H3K27Ac peak (Fig-
ure 3C), we initially thought that most genes in the region
would be controlled by the super-enhancers and not by
E7. Surprisingly, we found that many genes within +/− 5
Mb from E7 were downregulated upon deletion of the en-
hancer (Figure 3A). Specifically, five genes were downreg-
ulated within +/− 1 Mb of E7, including the non-coding
CASC8RNA (in which E7 resides), which was reduced 1.5-
fold. Of note, deletion of E7 also had effects on genes that
were not nearby, causing the up- or downregulation of more
than 1000 genes in the genome, most of which were on other
chromosomes (Table 1). In fact 25 genes were reproducibly
downregulated more than 5-fold in the E7-deleted cells; a
list of all downregulated genes in E7-deleted cells is found
inAdditional File 5.We also noted that deletion of the small
E7 enhancer resulted in loss of H3K27Ac peaks at the edge
of the nearby super-enhancer (Figure 3C) and at another
super-enhancer located ∼2 Mb from E7.
The size or presence of an H3K27Ac peak does not always
correlate with effects on the transcriptome
As an approach to understanding the genome-wide changes
in gene expression seen upon deletion of E7, we also deleted
a strong H3K27Ac peak on chromosome 18 (termed 18qE
for ‘enhancer on chromosome 18q’). The 18qE region has a
more robust H3K27Ac peak in HCT116 cells than does E7
(Figure 1A) and is covered by H3K27Ac in many cell types
(see the layered H3K27Ac track in Figure 1B). Similar to
E7 (Figure 4), 18qE is bound by TCF7L2, a site-specific TF
that has been implicated as the downstream regulator of the
WNT pathway that drives the development of colon can-
cer (25–29) and by CTCF, a multi-functional protein that
is thought to be involved in gene regulation and chromo-
somal structure (30–34). However, we note that the binding
of TCF7L2 and CTCF is not as strong at 18qE as at E7.
For comparison, we also deleted another region on chromo-
some 18 (termed 18qNE for ‘no enhancer on chromosome
18q’) that does not have H3K27Ac or TCF7L2 binding but
is bound by CTCF. Interestingly, we found that deletion of
the large 18qE enhancer had little effect on gene expression,
causing changes similar to those seen when the 18qNE re-
gion (which completely lacks H3K27Ac) was deleted (Table
1).
The differential effects on the transcriptome seen when
E7 versus 18qE was deleted from HCT116 cells suggest
that the presence of a robust H3K27Ac peak might not be
strongly correlated with effects on the transcriptome, but
that other, as of yet unknown characteristics of the region
may be critical. Interestingly, although many cell types do
show a strong H3K27Ac peak in the E7 region (see Figure
1B), there is no H3K27Ac peak in HEK293 cells (Figure 4).
However, there is a very strong CTCF binding site at E7 in
HEK293 cells. To compare the effects of deleting a genomic
region that is marked by H3K27Ac in one cell type but not
in another, we deleted E7 in HEK293 cells. We found that
deletion of this region in HEK293 cells caused changes in
hundreds of genes, includingMYC, which showed a robust
5-fold decrease in expression (Figure 5 and Table 1); a list
of all downregulated genes in HEK293 E7-deleted cells is
found in Additional File 5. We note that HCT116 cells are
derived from the colon whereas HEK293 cells are derived
from the kidney. Therefore, downstream signaling pathways
affected by MYC are likely to be quite different in the two
cell types; as expected most of the genes (other than MYC)
that were altered in the HCT116 and HEK293 cells upon
deletion of E7 were different.
Characterization of the genome-wide changes in the
epigenome upon enhancer deletion
As another approach to characterizing the effects of dele-
tion of an specific enhancer, we performed a genome-wide
analysis of H3K27Ac in the E7-deleted cells. We analyzed
the H3K27Ac patterns within +/− 100 Kb of upregu-
lated and downregulated genes in the E7-deleted cells. We
found that many of the downregulated genes in E7-deleted
cells (Additional File 6A) had decreased H3K27Ac peaks
nearby. In contrast, many of the upregulated genes in E7-
deleted cells (Additional File 6B) had increased H3K27Ac
peaks nearby; see Additional File 7 for the differential
H3K27Ac peak analysis. For example, in E7-deleted cells
there was a large downregulation of DPEP1 and ANXA10
mRNA, with concomitant decrease in the H3K27Ac marks
near those genes. In contrast, the H3K27Ac pattern was in-
creased near upregulated genes such as FGF9 and VSNL1.
Cell growth is affected by deletion of enhancer E7
Deletion of E7 in both HCT116 cells and in HEK293 cells
caused decreased expression ofMYC, a well-characterized
oncogene (35–37). Therefore, it is possible that deletion of
the E7 enhancer affected cell proliferation via downregula-
tion of MYC protein. To test this hypothesis, we performed
cell number and colony forming assays in control and E7-
deleted HCT116 and HEK293 cells. HCT116 control and
E7-deleted cells were plated at two different densities and
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Figure 3. Gene expression and H3K27Ac changes upon deletion of E7 in HCT116 cells. (A) The Y-axis shows log2 fold changes in gene expression in the
E7-deleted cells throughout a +/− 5 Mb region from E7, with genes showing decreased expression upon enhancer deletion having negative numbers and
genes showing increased expression upon enhancer deletion having positive numbers. (B) Shown are the H3K27Ac patterns in independent replicates of
control and enhancer-deleted cells within an ∼3 Mb region near the E7 enhancer (located within the purple box, which is shown in an expanded view in
panel C). Also shown is the H3K4me3 pattern to identify promoter regions. The Y-axis indicates the peak height and the X-axis indicates the genomic
location; only those genes significantly downregulated in the deleted cells are indicated in red below the H3K4me3 track. (C) The H3K27Ac patterns in
control and deleted cells are shown for the region nearby E7 (red arrow), showing loss of the E7 H3K27Ac peak, as well as loss of H3K27Ac signal at the
right side of the nearby large enhancer region.
Figure 4. H3K27Ac, TCF7L2, and CTCF binding profiles of E7, E24, 18qE and 18qNE. Shown are the H3K27Ac, TCF7L2 and CTCF binding patterns
at (A) the E7 enhancer in HCT116 cells, (B) the E7 enhancer in HEK293 cells, (C) 18qE, an intergenic H3K27Ac peak on chromosome 18, in HCT116
cells and (D) 18qNE, an intergenic region on chromosome 18 that lacks the H3K27Ac mark, in HCT116 cells. The Y-axis indicates the peak height and
the X-axis indicates the genomic location; the boxes indicate the region deleted by the CRISPR/Cas9 method.
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Figure 5. Gene expression and H3K27Ac changes upon deletion of E7 in HEK293 cells. The Y-axis shows log2 fold changes in gene expression in the
E7-deleted cells throughout a +/− 5 Mb region from E7, with genes showing decreased expression upon enhancer deletion having negative numbers and
genes showing increased expression upon enhancer deletion having positive numbers; only those genes significantly downregulated in the deleted cells are
indicated in red below the H3K4me3 track.
grown for 72 or 96 h. Cell number (Figure 6A) and colony
formation (Figure 6B) is reduced inE7-deleted cells, as com-
pared to control cells. As shown in Additional File 8, E7-
deleted cells also havemorphological changes and increased
contact inhibition. TheHEK293 cells in which the enhancer
was deleted showed drastic changes in cell morphology, sug-
gesting that the ability to form large colonies was affected
upon enhancer deletion. Thus, deletion of the region con-
taining rs6983267 caused downregulation of MYC, large
changes in the transcriptome, and changes in responses in
cell growth assays in both HCT116 and HEK293 cells, de-
spite the fact that the epigenomic profile of E7 is quite dif-
ferent in the two cell types.
DISCUSSION
Employing CRISPR/Cas9 nucleases, we deleted a CRC
risk-associated enhancer from the genome of HCT116
colon cancer cells and analyzed effects on the transcrip-
tome and epigenome. We found widespread changes in ex-
pression and H3K27Ac patterning in the enhancer-deleted
cells. However, deletion of a robust H3K27Ac peak (18qE)
not associated with CRC did not cause similar changes in
gene expression. Interestingly, deletion of the E7 region en-
compassing the CRC-associated risk SNP in HEK293 cells,
at which there is no detectable H3K27Ac peak but there
is a robust CTCF site, also caused widespread changes in
gene expression. Finally, we show that deletion of the E7 re-
gion affects gene expression and cell culture assays in both
HCT116 and HEK293 cells, likely due to downregulation
of the MYC oncoprotein.
Large-scale GWAS efforts have identified sets of SNPs
associated with a particular disease, such as colon cancer.
If a SNP falls within an exon and changes the coding po-
tential of that gene, investigators have suggested that the
identified gene is likely to be associated with increased risk
for that disease. However, most GWAS-identified SNPs do
not fall within exons and thus the mechanism by which
these SNPs might affect disease has not been clear (38,39).
Recent studies have shown that many of the GWAS index
SNPs and SNPs in high LD with the GWAS index SNPs
fall within regulatory elements such as promoters and en-
hancers. In the case of the SNPs falling close to transcrip-
tion start sites, it has been assumed that they cause changes
in expression of the gene regulated by that promoter. In the
case of SNPs falling within enhancer regions (as defined
by the H3K27Ac mark), it is more difficult to understand
how the SNP affects gene expression because enhancers can
work at a great distance, in either orientation, and often skip
over the nearest transcription start site to regulate genes far-
ther away (21,23). We reasoned that precise deletion of an
enhancer should identify genes regulated (directly and indi-
rectly) by that enhancer, with nearby downregulated genes
being possible direct target genes. As a test of this exper-
imental approach, we deleted a CRC risk-associated en-
hancer from the human genome. We found that deletion
of the CRC risk-associated enhancer, but not a non-risk-
associated enhancer, caused reproducible changes in expres-
sion of at least one gene within +/− 1 MB of the enhancer.
It is important to note that a promoter can be regulated
by several different enhancers; if a gene is regulated equally
by two enhancers, then a 50% drop in RNA levels is what
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Figure 6. Cell number is affected by deletion of enhancer 7. (A) Shown are the relative cell numbers 72 h after plating two different control clones or the
E7 deleted clone at 1 × 10e4 cells (top panel) or 96 h after plating two different control clones or the E7 deleted clone at 2.5 × 10e3 cells (bottom panel).
The Y-axis indicates relative cell numbers from an average of four replicate wells, as measured by absorbance of products of the WST-1 assay. Student’s
t-test was used for significance and * indicates a P-value < 0.005. (B) Shown are colony forming assays for control and E7-deleted HCT116 cells. A total
of 1500 cells were seeded per well and after 2 weeks colonies were stained with crystal violet. At least three replicates were performed; additional replicates
are shown in Additional File 8. (C) Shown are colony forming assays for control and E7-deleted HEK293 cells. A total of 6500 cells were seeded per well
and after two weeks colonies were stained with crystal violet. At least three replicates were performed; additional replicates are shown in Additional File
8.
would be expected upon deletion of one of the enhancers.
Most of the nearby genes that were downregulated upon
enhancer deletion were expressed at 20–65% of their ex-
pression level in control cells, suggesting that the enhancers
contributed to expression of these genes, but were not the
sole regulatory elements controlling the activity of the tar-
get promoters.
We note that deletion of the CRC risk-associated en-
hancer not only affected nearby genes but also affected the
regulation of hundreds of other genes, some on the same
chromosome but very far from the enhancer and still more
located on other chromosomes. There have not yet been
sufficient studies to know how far a gene can be from an
enhancer (or even if it can be on a different chromosome)
and still be a ‘direct’ target. One approach that is used to
identify direct targets is to use 3-dimensional (3D) loop-
ing assays. A recent study showed that 57% of enhancer–
promoter loops span more than 100 Kb (40). Importantly,
our results are supported by a previous study in which the
E7 enhancer region was shown to interact with the MYC
and PVT1 promoters in colon cancer cells (41,42). Studies
in other cell types have also provided evidence that E7 inter-
acts with theMYC gene (43–46). We also observed a reduc-
tion in the lncRNACCAT1 in the E7-deletedHCT116 cells.
Others have suggested that reduction of CCAT1 can reduce
long-range interactions between theMYC promoter and its
enhancers (47). Thus, it is possible that direct downregula-
tion ofCCAT1 (which is located 182Kb fromE7) caused an
indirect downregulation ofMYC. However, looping assays
should be interpreted with caution, as different assays give
different results (48). Also, it is not yet known if all loops
represent functional enhancer–promoter interactions or if
some loops may play other roles, such as structural compo-
nents of chromatin (24).
We have shown that deleting E7 not only affects expres-
sion of relatively ‘nearby’ genes but that it also causes ma-
jor changes in the transcriptome. In fact, the genes that
changed the most in expression are on other chromosomes
(Figure 7). In our experiments, we have attempted to con-
trol for effects on the transcriptome not related to enhancer
deletion. As described in detail in the ‘Materials and Meth-
ods’ section, all differential gene expression analysis was
performed using a set of control clones that were selected
in the same way as were the clones of enhancer-deleted
cells (i.e. sorting via FACs for single colonies after trans-
fection with Cas9-GFP and the guide RNA vector). Also,
we show that deletion of other genomic regions does not
lead to genome-wide changes in gene expression; the 18qE
and 18qNE clones have essentially identical gene expression
profiles as do the control clones, indicating that the robust
changes in gene expression observed when E7 was deleted
were not general effects due to the CRISPR/Cas9 technol-
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Figure 7. Circos plots for top downregulated genes. The circos plots show the chromosomal location of the top 25 downregulated genes (>2-fold) for each
enhancer deletion (green for protein-coding genes and orange for non-coding genes, with the thickness of the line indicating the extent of the fold-change;
for 18qE and 18qNE only three downregulated genes were identified and for 18qNE these downregulated genes were decreased <2-fold.
ogy. In addition, we note that we have used two indepen-
dent sets of guide RNAs to delete E7. After showing that
MYC was downregulated in HCT116 cells using a set of
guide RNAs that deletes a 2.6 Kb region encompassing the
E7 enhancer, we then shifted the guide RNAs slightly closer
together such that they target a 2 Kb region within the orig-
inal 2.6 Kb region (removing the same TF binding sites)
and isolated another clone of HCT116 cells in which all al-
leles of E7 were deleted. Analysis of this clone by qRT/PCR
showed thatMYC was downregulated 2.9 fold (P < 0.002)
using these independent guide RNAs. We used this second
set of guide RNAs to delete E7 in HEK293 cells. Thus,
in both HEK293 and HCT116 (using independent sets of
guide RNAs), we identifiedMYC as a target gene. The use
of two different sets of guide RNAs alleviates concerns that
the effects on gene expression are due to specific off tar-
get effects of the guide RNAs targeting E7. We also note
that the concomitant changes in expression and H3K27Ac
patterns (two completely independent methodologies, per-
formed on different days with different replicates of cells)
support the conclusion that the genes identified as deregu-
lated were not identified simply due to the method of RNA
analysis.
It is likely that most of the altered (indirect) gene reg-
ulation in the E7-deleted cells is initiated by reduction of
MYC RNA, followed by changes in the MYC regulatory
network. Using Ingenuity Pathway Analysis, we found that
61 of the downregulated genes are known components of
the MYC network (Additional File 9); other genes show-
ing altered expression may be downstream targets of the
MYC-regulated genes. Deregulated expression of MYC ex-
pression is a hallmark feature of many types of cancer and
frequently predicts a poor patient outcome (35,49). Ac-
cordingly, there is a strong push to develop therapeutic in-
hibitors of MYC function (36). Perhaps inactivation of cell
type-specific enhancers that regulateMYC expression is an
alternate to developing chemotherapeutic agents that tar-
get MYC itself. Interestingly, we have shown changes in cell
culture responses upon deletion of E7 in both HCT116 and
in HEK293 cells; the observed responses could be due to
decreased cell proliferation, increased cell death or a com-
bination of both.We note that Sur et al. deleted a region ho-
mologous to E7 in the mouse genome and observed slight
changes in Myc expression in the colon, but a significant
change in tumor formation in the colons of Apcmin mice
(50). In addition, we have observed that E7-deleted cells are
very difficult to trypsinize from the cell culture plates (data
not shown). Others have previously reported that MYC is
involved in suppressing cell adhesion molecules (51) and we
find that many integrin molecules are significantly upregu-
lated at least 2-fold in E7-deleted cells (e.g. ITGA3, ITGA4,
ITGA5, and ITGA6 in HCT116 and ITGA3, ITGA7, and
ITGAV in HEK293). These molecules are not upregulated
in the other deleted cells.We note that bothMYC andPVT1
RNAs are downregulated in HCT116 cells after deletion of
E7. Tseng et al. (52) showed that PVT1 RNA levels and
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MYC protein expression correlate in primary human tu-
mors and, in HCT116 cells, loss of PVT1 results in reduced
MYC protein, reduced proliferation and impaired colony
formation in soft agar. Therefore, the reduction in PVT1
RNA that occurs upon deletion of E7 may cause an even
larger effect onMYC protein levels, and more effects on the
MYC regulatory network, than would be expected by the
changes inMYC RNA alone.
In conclusion, we have used the CRISPR/Cas9 technol-
ogy to delete an enhancer that harbors a SNP associated
with an increased risk for CRC.We show that loss of this en-
hancer causes changes in expression of hundreds of genes.
However, we also show that the size of the H3K27Ac peak
does not necessarily correlate with the effect of a distal ele-
ment on gene regulation. Our results are supported by a re-
cent study in which 2000 predicted enhancers were analyzed
for activity in a reporter assay. The investigators found that
enhancer fragments having ‘weaker’ H3K27Ac signals can
drive expression as well as, if not better than, enhancer frag-
ments having ‘stronger’ H3K27ac signals (53). Recent stud-
ies have shown that deleting or inverting a CTCF site can
affect loop formation and cause gene expression changes
(54,55). In the case of the E7 enhancer, it is possible that
the effects on gene expression that we observed are due to
changes in the 3D architecture of the chromosome due to
removal of a CTCF site involved in looping; there is robust
CTCF binding at the E7 enhancer in parental HCT116 and
HEK293 cells. One could imagine that altering the 3D chro-
mosomal domain in which a gene resides could have more
dramatic effects on gene expression than removal of a sin-
gle H3K27Ac-marked enhancer (such as 18qE) that is not
robustly bound by CTCF. Clearly, further experiments are
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